Back to Search
Start Over
The impact of vedolizumab on COVID-19 outcomes among adult IBD patients in the SECURE-IBD registry
- Source :
- Journal of Crohn's & Colitis
- Publication Year :
- 2021
- Publisher :
- Oxford University Press, 2021.
-
Abstract
- Background The impact of immune-modifying therapies on outcomes of coronavirus disease 2019 [COVID-19] is variable. The purpose of this study was to determine the impact of vedolizumab [VDZ], a gut-selective anti-integrin, on COVID-19 outcomes in inflammatory bowel disease [IBD] patients. Methods Using data from the Surveillance of Coronavirus Under Research Exclusion for IBD [SECURE-IBD], an international registry of IBD patients with confirmed COVID-19, we studied the impact of VDZ on COVID-19 hospitalization and severe COVID-19 [intensive care unit stay, mechanical ventilation and/or death]. Results Of 3647 adult patients on any IBD medication in the registry, 457 [12.5%] patients were on VDZ. On multivariable analyses using backward selection of covariates, VDZ use was not associated with hospitalization or severe COVID-19 when compared with patients on all other medications (adjusted odds ratio [aOR] 0.87; 95% confidence interval [CI] 0.71, 1.1 and aOR 0.95; 95% CI 0.53, 1.73, respectively). On comparing VDZ monotherapy to anti-tumour necrosis factor [anti-TNF] monotherapy, the odds for hospitalization, but not severe COVID-19, were higher [aOR CI 1.39; 95% CI 1.001, 1.90 and aOR 2.92; 95% CI 0.98, 8.71, respectively]. In an exploratory analysis, VDZ monotherapy, compared to anti-TNF monotherapy, was associated with new-onset gastrointestinal symptoms at the time of COVID-19, especially among patients whose IBD was in remission. Conclusions COVID-19 outcomes among IBD patients on VDZ are comparable to those on all other therapies. Hospitalization, but not severe COVID-19, is more likely with VDZ monotherapy than with anti-TNF monotherapy. Overall, VDZ appears to be safe in IBD patients with COVID-19.
- Subjects :
- 0301 basic medicine
Crohn’s disease
vedolizumab
Adult
Male
medicine.medical_specialty
Disease
outcomes
Antibodies, Monoclonal, Humanized
Inflammatory bowel disease
Vedolizumab
law.invention
03 medical and health sciences
0302 clinical medicine
Gastrointestinal Agents
law
inflammatory bowel disease
Internal medicine
medicine
Humans
Registries
AcademicSubjects/MED00260
ulcerative colitis
Crohn's disease
Coronavirus disease 2019
business.industry
SARS-CoV-2
Gastroenterology
COVID-19
General Medicine
Odds ratio
Middle Aged
medicine.disease
Inflammatory Bowel Diseases
Ulcerative colitis
Intensive care unit
Confidence interval
030104 developmental biology
030211 gastroenterology & hepatology
Original Article
Female
business
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 18764479 and 18739946
- Database :
- OpenAIRE
- Journal :
- Journal of Crohn's & Colitis
- Accession number :
- edsair.doi.dedup.....48f3896fcf66ee47d9d7b4a484075e49